Harmony Biosciences rises after quarterly results beat

Shares of rare neurological disease-focused pharma company Harmony Biosciences rise HRMY.O 3.5% to $31 premarket

HRMY posts Q1 adj. profit of 78 cents per share, above analysts' estimate of 58 cents per share - data compiled by LSEG

Company posts Q1 product revenue of $184.73 million, beating analysts' estimate of $182.9 million

Company maintains its 2025 product revenue of $820 million to $860 million compared with estimates of $839.89 million

As of last close, HRMY has fallen 12.9% YTD